The Tufts Center for the Study of Drug Development (CSDD) published its Outlook 2013 report on pharmaceutical trends. Although Tufts CSDD Director Kenneth I Kaitlin is optimistic about the future of dug innovation, he believes companies needs to identify and reduce R&D inefficiency. Patent expiration of multiple top-selling drugs and sparse pipelines are leading many drug developers to streamline R&D process by embracing new models of drug development. Kaitlin noted that many companies are reducing costs and improving clinical success rates by using biomarkers and statistical analysis to enhance study design. He also commented on the emergence of open innovation models that could potentially lead to shared knowledge and ultimately increased R&D efficiency. To read an article on this report in PharmTimes Online, click here. For highlights of the Tufts CSDD Outlook 2013 report, click here.
Need help with accelerating your drug development efforts or expediting a clinical research study? Contact us at info@pearlirb.com.